Bioventix PLC (LON:BVXP) had its Corporate rating reiterated by FinnCap

Analyst Ratings For Bioventix PLC (LON:BVXP)

Story continues below

Today, FinnCap reiterated its Corporate rating on Bioventix PLC (LON:BVXP).

There are 0 Strong Buy Ratings, no Sell Ratings, no Hold Ratings, no Buy Ratings on the stock.

The current consensus rating on Bioventix PLC (LON:BVXP) is N/A with a consensus target price of GBX 2,650 per share, a potential .

Some recent analyst ratings include

  • 10/8/2018-Bioventix PLC (LON:BVXP) had its Corporate rating reiterated by FinnCap

    About Bioventix PLC (LON:BVXP)
    Bioventix PLC, a biotechnology company, manufactures and supplies sheep monoclonal antibodies (SMAs) for use in diagnostics applications. The company offers a portfolio of purified SMAs for the clinical diagnostics market for thyroid, vitamin D, cardiovascular, drugs of abuse, fertility testing, infectious disease, oncology, and miscellaneous. It also provides contract SMAs and recombinant services. The company was founded in 2003 and is based in Farnham, the United Kingdom.

    Recent Trading Activity for Bioventix PLC (LON:BVXP)
    Shares of Bioventix PLC closed the previous trading session at 3,025.00 −195.00 6.06% with shares trading hands.

    An ad to help with our costs